Research Study

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.
Principal Investigator 
Matthew Bennett

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03464019
Status 
Recruiting
Study Start/End 
Oct 11, 2018 to Nov 1, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Matthew Wei, Research Coordinator
Phone 
604-875-5104
Email Address 
matthew.wei@vch.ca
Purpose of Study 

The purpose of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of Paroxysmal Supraventricular Tachycardia (PSVT) in an outpatient setting.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.